INTRODUCTION
Rituximab (MabThera/Rituxan), a chimeric anti-CD20 monoclonal antibody, is effective and well tolerated in patients with B-cell lymphoproliferative disorders, including non-Hodgkin lymphoma and chronic lymphocytic leukemia.
1-5 For patients with follicular lymphoma (FL), induction with rituximab plus chemotherapy followed by rituximab maintenance is the mainstay of therapy. [5] [6] [7] [8] Rituximab is typically infused intravenously (IV) over many hours 9 and thus, subcutaneous (SC) administration of rituximab, which could substantially shorten administration time, is being investigated. SC administration was made possible by hyperconcentrating rituximab (12-fold) compared with the IV formulation and including the enzyme recombinant human hyaluronidase (rHuPH20) as an excipient.
10,11 rHuPH20 temporarily cleaves hyaluronan fibers in the interstitial tissue, thereby facilitating the SC injection of large volumes, as demonstrated in other settings. [11] [12] [13] [14] [15] Switching from IV to SC administration may also improve adverse event (AE) profiles, increase patient convenience, and improve cost-effectiveness, as previously shown by the introduction of trastuzumab JOURNAL OF CLINICAL ONCOLOGY and alemtuzumab SC administration. 16, 17 Delivery of rituximab via the SC route is suited to the use of a fixed dose, a relatively recent concept for administration of monoclonal antibodies, supported by growing evidence for a minimal influence of body weight on exposure variability for these agents. 18 For the clinical development of SC rituximab, we hypothesized that an SC dose that achieved noninferior serum trough concentrations (C trough ) would result in at least the same degree of target-site saturation and, hence, at least the same efficacy as IV dosing. To the best of our knowledge, SparkThera (A Pharmacokinetic Study of Subcutaneous and Intravenous MabThera [Rituximab] in Patients With Follicular Lymphoma; BP22333; two-stage, phase IB) was the first clinical study to investigate SC rituximab as maintenance therapy in patients with FL. SparkThera incorporated a customized pharmacokinetic model that allowed comparison of SC and IV administration under controlled conditions. Here, we describe the design and final results of the study.
PATIENTS AND METHODS

Patients
Eligible patients were age Ն 18 years with CD20-positive FL grades 1, 2, or 3a; life expectancy Ն 6 months; and Eastern Cooperative Oncology Group performance status Յ 2. Patients must have demonstrated a partial or complete response following induction treatment with IV rituximab given alone or with chemotherapy. Eligible patients received one or more doses of IV rituximab as maintenance therapy and had one or more doses remaining. Exclusion criteria included recent infections or a history of hepatitis B.
An FL maintenance population was chosen because pharmacokinetic variability was expected to be lower than the induction setting as a result of the lower tumor load in responders eligible for maintenance. Before final dose selection, exposure to SC rituximab was limited to a single administration to prevent potential underexposure of patients being maintained in remission with IV rituximab.
Study Design and Treatment
SparkThera was an open-label, multicenter, phase IB study of SC rituximab as maintenance treatment in patients with FL (Figs 1 and 2) . The study was conducted in 22 countries around the world (in Europe, Canada, South America, Asia-Pacific, and the Middle East) and was performed in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The independent ethics committee at each study center approved the study protocol. Rituximab was provided as a 10-mL solution with a concentration of 120 mg/mL rituximab (F. Hoffmann-La Roche, Basel, Switzerland) and 2,000 U/mL rHuPH20.
Patients were enrolled onto either stage 1 or stage 2 (Figs 1 and 2) by using a block-size randomization scheme, stratified by their maintenance regimen (every 2 v every 3 months). SC rituximab was required to be injected into the abdomen at a single site. The primary objective of stage 1 was to identify a dose of SC rituximab that yielded a serum C trough in the range achieved with IV rituximab (dose finding). In stage 2, the primary objective was to demonstrate the noninferiority of C trough (described in Statistical Analysis) in patients administered SC rituximab at the dose determined from stage 1 versus IV rituximab.
The variation in the number of prestudy treatment cycles patients had received, residual rituximab serum concentrations from IV infusions administered before study entry, and the effects of the underlying crossover from IV to SC administration limited the value of using measured data and necessitated a modeling approach. C trough was selected as the primary pharmacokinetic parameter because it was expected to reflect the degree of target-site saturation during the entire dosing interval. Secondary end points of both stages included assessments of area under the concentration-time curve (AUC), safety, immunogenicity, and B-lymphocyte levels.
Dose selection for stage 1 was supported by bioavailability data for SC rituximab from a preclinical animal model and the known bioavailability of other monoclonal antibodies after SC administration in humans (40% to 100%). . Following an interim analysis, an SC rituximab 800 mg/m 2 cohort was opened to support selection of the fixed dose for stage 2 by enabling interpolation over a wider range of exposure (further rationale in the Data Supplement).
The first patients treated with each of the SC rituximab doses were evaluated for safety and tolerability for Ն 4 days before a second patient was treated. After a single SC or IV dose, all patients continued IV rituximab until completion of 2 years of maintenance. Following selection of the final SC dose, patients randomly assigned to an SC dose group could choose to receive any remaining doses as SC rituximab, provided they had completed at least 1 year of maintenance with IV rituximab.
In stage 2, patients were randomly assigned 1:1 to the fixed SC dose determined in stage 1 (1,400 mg) or to the IV dose of 375 mg/m 2 until 2 years of maintenance was completed. After treatment completion, patients in both stages were observed for 9 months at 3-month intervals.
Assessments and Evaluations
Pharmacokinetics and pharmacodynamics. Blood samples for pharmacokinetic analyses were drawn from all patients throughout the study until the last follow-up visit (9 months after the last maintenance dose) for rituximab and during the first cycle in patients receiving SC rituximab for rHuPH20. Pharmacokinetic sampling times, assays, power calculations, and data modeling are detailed in the Data Supplement. Blood samples for measuring CD19 ϩ B lymphocytes were taken before each rituximab administration and at each follow-up visit.
Safety and immunogenicity. Safety and tolerability data were collected throughout the study. AEs were summarized by using the Medical Dictionary for Regulatory Activities (MedDRA) and were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). Any AE that occurred during or within 24 hours of treatment and was considered to be related to rituximab by the investigator was defined as an administration-related reaction (ARR).
Samples for measuring antirituximab and anti-rHuPH20 antibodies were collected throughout the study. Details on sampling and assays can be found in the Data Supplement. Assessments and procedures were identical for both stages of the study unless otherwise specified.
Dose Interpretation With Pharmacokinetic Analysis
Stage 1. Pharmacokinetic data from patients receiving IV and SC rituximab in stage 1 of the study were included in a population pharmacokinetic model (described in the Data Supplement). This model was initially derived from six clinical studies in the non-Hodgkin lymphoma induction setting 21 and allowed comparison of SC and IV administration of rituximab under similar conditions. After stage 1, the model was used to simulate an SC rituximab fixed dose that would result in noninferior C trough compared with IV rituximab 375 mg/m 2 during a 2-or 3-month maintenance regimen in a population with a body surface area (BSA) of 1.92 Ϯ 0.247 m 2 . Stage 2. At the end of stage 2, the population pharmacokinetic parameters were updated by using the combined data from both stages. Individual pharmacokinetic parameters derived from the updated model were combined with a hypothetical sequence of induction (IV or SC; every 2 months or every 3 months during maintenance) to generate individual predicted serum concentration profiles. From these profiles, C trough and AUC over the dosing interval (AUC ), were calculated by model-independent means at cycle 2 of maintenance. A noninferiority test then compared rituximab C trough and AUC levels with both routes of administration. 
Statistical Analysis
In stage 1, sample size was based on the model's precision of estimation: 30 patients per SC group and 15 patients per IV group. In stage 2, the sample size of 70 patients per treatment arm was based on rituximab C trough levels. Noninferiority would be considered confirmed if the lower boundary of the two-sided 90% CI of the geometric mean ratio C trough SC :C trough IV was more than 0.8.
Pharmacokinetic analyses included all patients with available assessments. The safety analysis included all patients who had received one or more doses of SC rituximab or IV rituximab within the study. B-cell levels and safety variables were summarized descriptively.
RESULTS
Patients
In stage 1, 124 patients were randomly assigned (Fig 1) , and at analysis (May 11, 2012), 101 patients (81%) had completed treatment, 49 (40%) continued in follow-up, and 47 (38%) had completed the study.
In stage 2, 157 patients were randomly assigned (Fig 1) ; at analysis, 38 (49%) SC and 33 (42%) IV patients were receiving treatment, 22 (28%) SC and 24 (30%) IV patients continued in follow-up, and six (4%) had completed the study. Median treatment duration on study was 14.8 months (range, 0 to 19 months) for SC rituximab and 13.8 months (range, 0 to 19 months) for IV rituximab.
Baseline characteristics were similar across treatment groups in both stages of the study (Table 1) . SC rituximab injections of 1,400 mg (n ϭ 537) had a median duration of administration of 5.9 minutes (range, 2.0 to 13.4 minutes).
Pharmacokinetics
Rituximab (Fig  3) . Absolute bioavailability of the SC formulation was estimated at 65%.
By using the pharmacokinetic model, which combined C trough data from all dose-finding groups, serum C trough and AUC values were simulated 100 times by comparing IV rituximab 375 mg/m 2 with fixed doses of SC rituximab between 1,100 and 1,400 mg and assuming a BSA distribution of 1.92 Ϯ 0.24 m 2 . Dose selection was performed on C trough concentrations at cycle 2 of maintenance.
The model predicted that a fixed SC dose of 1,400 mg would yield a noninferior serum C trough and comparable AUC compared with IV rituximab, regardless of BSA or whether rituximab was given every 2 or every 3 months (Data Supplement). A dose of 1,400 mg was selected for assessment in stage 2 to ensure that all patients, including those at the upper end of the BSA range, would achieve an SC:IV C trough ratio of at least 0.8. Considering the clinical evidence that rituximab has a wide therapeutic window 22, 23 and has an established efficacy and safety profile in B-cell lymphomas, 3,24 preventing underdosing in all patient subgroups was considered to be the first priority.
The stage 2 primary end point was met; SC rituximab 1,400 mg achieved noninferior C trough compared with IV rituximab 375 mg/m 2 . Geometric mean C trough SC :C trough IV ratios were 1.24 and 1.12 for the 2-and 3-month regimens, respectively (Fig 4) , and the lower limits of the two-sided 90% CI (1.02 and 0.86, for the 2-month and 3-month regimens, respectively) exceeded the protocol-specified noninferiority limit (C trough SC :C trough IV ratio of 0.8; Fig 4) . The geometric mean AUC over the dosing interval AUC SC :AUC IV ratio was 1.35, and the lower limit of the two-sided 90% CI was 1.23 for both 2-and 3-month regimens, indicating that AUC after SC rituximab was at least as high as that after IV rituximab (Fig 4) . C trough and AUC geometric mean values are provided in the Data Supplement.
Pharmacodynamics
CD19 ϩ B lymphocytes were depleted at enrollment and throughout the study for all patients, as expected during maintenance. Evidence of B-cell repletion was observed 9 months after the last rituximab (IV or SC) administration, but at the time of analysis, patient numbers were too small for any conclusions (only six patients had completed the 9-month follow-up visit).
Safety and Immunogenicity
In stage 1, the proportion of patients experiencing AEs and severe AEs was similar between the SC and IV groups ( Table 2 ). The majority of AEs were grade 1 or 2. Comparing events after a single cycle allowed direct comparison of SC versus IV administration (in contrast to overall events, in which patients had received both SC and IV rituximab). The most common AE in the single cycle of randomly assigned treatment and throughout stage 1 was ARR (more frequent with SC rituximab). Serious adverse events (SAEs) were experienced by 13% of patients receiving IV 375 mg/m 2 and 15%, 15%, and 8% of patients receiving SC 375, 625, or 800 mg/m 2 , respectively. Three SAEs (one in each of the SC cohorts) led to withdrawal from treatment (none were considered related to study treatment and all occurred when patients had received further cycles by IV infusion). There were no fatal AEs or other deaths in stage 1.
A total of 15, 12, and 16 eligible patients receiving SC rituximab 375, 625, and 800 mg/m 2 , respectively, in stage 1 (40%) chose SC administration for their remaining maintenance treatment. This choice was not actively encouraged, but investigators reminded patients of the option. The incidence of AEs in these patients was similar to that of other patients in stage 1 (who received only one dose of SC rituximab) but with fewer ARRs reported.
In stage 2, 61 patients (79%) in each group experienced one or more AEs (Table 2) , with reports of severe AEs balanced between the groups: 13 (17% for IV rituximab 375 mg/m 2 ) versus 14 (18% for SC rituximab 3 6  3a  2  6  4  12  8  20  2  13  16  21  19  25  Not known †  --2  5  2  13  -1  1 1,400mg)patients.Therewerenodeathsduringthestudy,butonepatient in the SC group died as a result of disease progression after withdrawal. The SC group had a higher rate of treatment-related AEs (48% v 25%) than the IV group, primarily as a result of a higher incidence of grade 1 or 2 ARRs (by prerequisite, events listed as ARRs were considered related by the investigator) in the SC rituximab group (31% v 4%), with erythema (13%) being the most common. No true anaphylactic reactions and no occurrences of cytokine release syndrome or tumor lysis syndrome were reported after SC rituximab administration. Antirituximab antibodies were not detected in stage 1. In stage 2, one patient (SC rituximab) tested positive during his first study cycle (predose, days 22 and 85). Further samples were not taken as the patient's disease progressed, leading to withdrawal from the study. Anti-rHuPH20 antibodies were detected in six patients (stage 1) and 
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DISCUSSION
In SparkThera, a pharmacokinetic model incorporating stage 1 data predicted that a fixed 1,400-mg SC rituximab dose would provide noninferior C trough levels compared with standard IV dosing. This was confirmed in stage 2: a fixed 1,400-mg SC dose was noninferior to IV maintenance dosing for 2-and 3-month regimens. Because rituximab has a wide therapeutic window, 22, 25 fixed dosing in adults is feasible if the dose is sufficient to prevent underdosing while maintaining an acceptable safety profile. The 1,400-mg SC dose should be viewed in the context that bioavailability estimated by using stage 1 data was 65%. To avoid underdosing individual patients, dose selection considered the variability of the pharmacokinetic data (Figs 3 and 4) . Furthermore, because the lower limit of the 90% CI of the C trough ratio (SC:IV) for the 3-month regimen was marginally above the threshold at 0.86, a lower dose would have failed the noninferiority test. On the basis of previous clinical investigations with high-dose rituximab, 22 ,25 the fixed-dose approach for SC administration was not expected to result in a greater risk of AEs. This was supported by a post hoc analysis of AEs by BSA showing comparable AE profiles for SC and IV (Data Supplement), even with approximately 35% higher mean AUC for SC rituximab 1,400 mg versus IV rituximab 375 mg/m 2 . In addition, an analysisofAEs,SAEs,andsevereAEsbyBSAperformedinstage2revealed similar incidence in both SC-and IV-treated patients within any given BSA category (Table 3 and Data Supplement) .
Overall, the safety profiles of the SC and IV formulations were comparable. No unexpected AEs were observed with SC dosing (including the incidence of severe AEs, SAEs, and AEs leading to withdrawal of treatment), and the profile was similar following SC or IV treatment. There were no treatment-related fatal AEs in either group. Common AEs related to rituximab, including infections, arthralgia, and nausea, were observed at rates in line with the established safety profile. A higher proportion of patients receiving SC rituximab experienced ARRs (mostly grade Ͻ 2), but this was not unexpected, and treatment was rarely required. A degree of expectancy bias in the study was difficult to avoid, especially because the SC formulation was introduced into an ongoing regimen. Furthermore, increased ARRs have been reported with SC formulations of other monoclonal antibodies. 26 SparkThera had a heterogeneous patient profile, but several other studies have shown that the safety profile of rituximab during maintenance therapy is similar regardless of treatment setting (firstline or relapse) or dosing interval for maintenance.
5,27-31 Continual B-cell depletion was observed with both SC and IV rituximab, indicating that rituximab mode of action 32 was unchanged by route of administration. Immunogenicity data were limited but encouraging, with few positive cases for antirituximab and anti-rHuPH20 antibodies, and there was no apparent correlation with safety.
Our study demonstrates that a fixed dose of SC rituximab 1,400 mg achieves noninferior serum C trough levels relative to standard IV dosing in the maintenance setting, with a comparable safety profile. Ongoing trials (including the phase III SABRINA study; A Study of MabThera [Rituximab] Subcutaneous Vs. MabThera [Rituximab] Intravenous in Patients With Follicular Non-Hodgkin's Lymphoma) 33 will provide additional insight regarding whether this C trough noninferiority translates into comparable efficacy as in other phase I studies evaluating SC administration of therapeutics. 34, 35 SparkThera provides an indicator of patient preference in the 43 stage 1 patients that chose SC rituximab for their remaining maintenance treatment. Furthermore, the annual amount of chair time saved per center by patients switching to SC rituximab has been estimated to range from 109 to 219 8-hour days, and the potential benefits for patients and health care systems are being investigated further. 36 Together, these findings suggest that SC administration of rituximab will improve the convenience of this drug, although additional investigation will be required to determine whether the SC route provides equivalent efficacy compared with that of IV administration.
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